ArriVent BioPharma, Inc. (AVBP)
↓ Download CSVKey ratios (FY2025)
-54.1%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Income | -$177.53M | -$94.31M | -$74.59M | — |
| Net Income | -$166.31M | -$80.49M | -$69.33M | — |
| EPS (Diluted) | $-4.32 | $-2.56 | $-32.38 | — |
| Total Assets | $333.17M | $274.94M | $163.10M | — |
| Total Liabilities | $25.95M | $17.29M | $11.80M | — |
| Shareholders' Equity | $307.22M | $257.65M | -$153.19M | -$85.11M |
| Cash & Equivalents | $45.54M | $74.29M | $150.39M | — |
| Operating Cash Flow | -$160.59M | -$70.21M | -$55.84M | — |
| Shares Outstanding | 42.45M | 33.71M | 2.75M | — |